Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,172.00
Ask: 12,174.00
Change: 108.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,062.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-G7 vaccine pledge is just a drop in the ocean, campaigners say

Fri, 11th Jun 2021 07:37

* G7 to pledge 1 billion vaccine doses

* Campaigners say G7 too slow, lacks ambition

* Britain to give 100 million doses

* UK says some countries using vaccines to exert influence
(Adds quotes from former UK PM Brown, Canadian pledge)

By Kate Holton and Elizabeth Piper

CARBIS BAY, England, June 11 (Reuters) - A Group of Seven
plan to donate 1 billion COVID-19 vaccine doses to poorer
countries lacks ambition, is far too slow and shows Western
leaders are not yet up to the job of tackling the worst public
health crisis in a century, campaigners said on Friday.

British Prime Minister Boris Johnson said he expected G7
leaders to agree the donations as part of a plan to inoculate
the world's nearly 8 billion people against the coronavirus by
the end of next year.

After U.S. President Joe Biden vowed to supercharge the
fight against the virus with a donation of 500 million Pfizer
shots, Johnson said Britain would give at least 100
million vaccines within a year.

Canada is expected to commit to sharing up to 100 million
doses. Other pledges may follow.

But health and anti-poverty campaigners said that, while
donations were a step in the right direction, Western leaders
had failed to grasp the exceptional efforts needed to beat the
virus. Help with distribution was also necessary, they said.

Former British prime minister Gordon Brown, who has been
pushing for richer countries to share more of the cost of
vaccinating developing countries, said the G7 pledges were more
akin to "passing round the begging bowl" than a real solution.

"It's a catastrophic failure if we can't go away in the next
week or two ... with a plan that actually rids the world of
COVID now we've got a vaccine," he told Reuters.

Alex Harris at Wellcome, a London-based science and health
charitable foundation, said the pledges did not go far enough.

"What the world needs is vaccines now, not later this year.
At this historic moment, the G7 must show the political
leadership our crisis demands," said Harris. "We urge G7 leaders
to raise their ambition."

The race to end a pandemic that has killed around 3.9
million people and sown social and economic destruction will
feature prominently at the three-day summit which began on
Friday in the English seaside resort of Carbis Bay.

British foreign minister Dominic Raab warned that other
countries were using vaccines as diplomatic tools to secure
influence. Britain and the United States said their
donations would come with no strings attached.

COVID-19 has ripped through the global economy, with
infections reported in more than 210 countries and territories
since the first cases were identified in China in December 2019.

'FAILURE'

As most people need two vaccine doses, and possibly booster
shots to tackle emerging variants, campaigners said world
leaders needed to go much further, and much faster.

"If the best G7 leaders can manage is to donate 1 billion
vaccine doses then this summit will have been a failure,"
Oxfam's health policy manager Anna Marriott said, adding that
the world would need 11 billion doses to end the pandemic.

Vaccination efforts so far are heavily correlated with
wealth: the United States, Europe, Israel and Bahrain are far
ahead of other countries. A total of 2.2 billion people have
been vaccinated according to Johns Hopkins University data.

Oxfam also called on G7 leaders to support a waiver on the
intellectual property behind the vaccines.

French President Emmanuel Macron has said intellectual
property rights should not hinder access to vaccines during a
pandemic, appearing to back Biden on the subject.

VACCINE OWNERSHIP?

But the pharmaceutical industry has opposed it, saying it
would stifle innovation and do little to increase supplies.
Britain, which backed Oxford-AstraZeneca's
not-for-profit shot, has said a patent waiver is not necessary.

Of the 100 million British shots, 80 million will go to the
COVAX programme led by the World Health Organization (WHO) and
the rest will be shared bilaterally with countries in need.

Johnson echoed Biden in calling on his fellow leaders to
make similar pledges and for pharmaceutical companies to adopt
the not-for-profit model during the pandemic. The U.S. Pfizer
donations will be supplied at cost.

Mass vaccination against the novel coronavirus is seen as
crucial to restoring economic growth and preventing the virus
from further mutation that could evade vaccines.

The British doses will be drawn from the stock it has
already procured for its domestic programme, and will come from
suppliers Oxford-AstraZeneca, Pfizer-BioNTech, Johnson &
Johnson's Janssen, Moderna and others.

(Additional reporting by Alistair Smout in London and David
Ljunggren in Ottawa; Editing by Guy Faulconbridge, Alex
Richardson and Emelia Sithole-Matarise)

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.